Livzon Pharmaceutical Group has been identified as an investor by Elicio Therapeutics, which just completed a series B round that takes its total financing to $63m.

Icosavax has launched out of University of Washington with $51m in series A funding to move a vaccine for respiratory syncytial virus into a phase 1b trial.

Frequency, a regenerative medicine developer based on MIT and Harvard research, priced shares at the bottom of its range to raise $84m in its IPO.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Alexandria Real Estate Equities-backed regenerative medicine developer floated at the bottom of its range while cutting the number of shares.

Customer engagement platform CrowdTwist has raised $20m from investors including Softbank Capital, KBS+ Ventures and Bertelsmann Digital Media Investments pre-acquisition.

Salesforce Ventures, a shareholder in nCino since 2015, has returned for an $80m round that brought the banking platform’s total funding to at least $218m.

Corporate venturing unit Capital One Growth Ventures supplied part of a series A round for recruitment analysis software provider Brightfield Strategies.

The genome mapping system developer took its total funding past the $100m mark in a round led by Hitachi High-Technologies.

Samsung, OCI, Regeneron, Handok, Johnson & Johnson and existing investor Novartis all took part in the cell therapy developer's latest round.